Montek (Sodium Molybdate (99mo))

Sodium molybdate releases molybdate ions that act as cofactors for several molybdoenzymes, supporting normal metabolic pathways. In diagnostic applications, the molybdate serves as a precursor to molybdenum‑99, which decays to technetium‑99m, enabling nuclear imaging procedures.

The dose of Montek is determined by the prescribing clinician based on the specific diagnostic or therapeutic context, the patient’s weight, renal function, and the intended use. Healthcare professionals set the appropriate amount and administration rate.

Safety data for sodium molybdate in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Montek, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Montek provides a high‑purity sodium molybdate solution that meets EU quality standards, offering reliable molybdenum‑99 precursor content. Compared with alternative molybdenum sources, it is formulated for both intravenous and ocular routes, allowing flexible use in a range of diagnostic protocols.

Montek must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken vigorously. Keep the vial in its original packaging until use and discard any solution that appears discolored or contains particles.

Montek is supplied as a sterile solution for intravenous infusion or ocular administration. The route, infusion rate, and volume are determined by the treating physician and are performed by qualified medical personnel in a controlled clinical environment.

Serious risks include severe allergic reactions such as anaphylaxis, significant hypotension, acute renal impairment, and hepatic dysfunction. Patients should be monitored closely during and after administration, and any signs of these reactions require immediate medical attention.

Montek should not be used in individuals with a known hypersensitivity to sodium molybdate or any of its excipients, in patients with severe renal or hepatic failure unless specifically indicated, and in pregnant or breastfeeding women unless the potential benefits outweigh the risks as judged by a healthcare professional.